tiprankstipranks
Trending News
More News >
Therma Bright (TSE:THRM)
:THRM
Advertisement

Therma Bright (THRM) AI Stock Analysis

Compare
63 Followers

Top Page

TSE:THRM

Therma Bright

(OTC:THRM)

Rating:45Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
Therma Bright's overall score is primarily driven by its challenging financial performance and weak technical indicators. The valuation reflects ongoing losses, while positive corporate events provide some potential upside.

Therma Bright (THRM) vs. iShares MSCI Canada ETF (EWC)

Therma Bright Business Overview & Revenue Model

Company DescriptionTherma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
How the Company Makes MoneyTherma Bright generates revenue through the sale and licensing of its proprietary medical devices and diagnostic tools. Key revenue streams include direct product sales to healthcare providers, distributors, and consumers, as well as licensing agreements with other companies in the healthcare sector. The company may also engage in strategic partnerships and collaborations to expand its market reach and enhance product offerings, thereby contributing to its earnings.

Therma Bright Financial Statement Overview

Summary
Therma Bright faces significant financial challenges, with ongoing profitability and liquidity issues despite revenue growth and a stable balance sheet.
Income Statement
42
Neutral
Therma Bright has experienced fluctuating revenue growth, with a notable increase in TTM (Trailing-Twelve-Months). However, the company remains unprofitable with negative net profit margins, EBIT, and EBITDA margins consistently over the years, indicating ongoing operational challenges.
Balance Sheet
55
Neutral
The company's balance sheet shows moderate leverage with a low debt-to-equity ratio. However, the return on equity is negative due to persistent losses. The equity ratio has improved, indicating better asset financing through equity rather than debt.
Cash Flow
38
Negative
Therma Bright's cash flow statement shows negative free cash flow and operating cash flow, highlighting liquidity issues. While there is some improvement in operating cash flow to net income ratio, the free cash flow to net income ratio remains weak.
BreakdownSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue26.07K23.90K139.43K3.88K3.78K
Gross Profit25.46K23.90K63.48K3.88K3.78K
EBITDA-2.34M-3.68M-5.83M-8.55M-606.31K
Net Income-2.45M-3.77M-5.88M-8.61M-626.68K
Balance Sheet
Total Assets3.19M2.21M4.00M2.24M1.15M
Cash, Cash Equivalents and Short-Term Investments1.10K182.24K3.08M1.78M1.06M
Total Debt65.39K90.39K110.55K40.00K95.94K
Total Liabilities1.87M2.16M1.25M927.12K924.32K
Stockholders Equity1.32M44.79K2.75M1.32M223.97K
Cash Flow
Free Cash Flow-1.01M-2.44M-3.80M-3.16M-104.94K
Operating Cash Flow-1.01M-2.17M-3.80M-2.86M-104.94K
Investing Cash Flow-138.26K-691.08K-204.93K-300.00K0.00
Financing Cash Flow966.40K-33.60K5.31M3.87M1.14M

Therma Bright Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.10
Negative
100DMA
0.15
Negative
200DMA
0.22
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
44.51
Neutral
STOCH
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:THRM, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.10, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.51 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:THRM.

Therma Bright Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
C$26.54M-23.87%18.97%17.57%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
49
Neutral
C$24.24M-163.62%245.01%-4.91%
48
Neutral
C$49.66M-291.48%-8.63%7.04%
45
Neutral
$4.26M-224.63%57.50%16.20%
44
Neutral
C$23.37M207.08%280.56%-7.28%
$3.54M
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:THRM
Therma Bright
0.08
-0.09
-53.13%
TSE:ASG
Aurora Spine
0.34
0.04
13.33%
TSE:PINK
Perimeter Medical Imaging AI
0.24
-0.24
-50.00%
TSE:TLT
Theralase Technologies
0.20
0.03
17.65%
TSE:VPT
VentriPoint Diagnostics
0.14
-0.06
-30.00%
PMEDF
Predictmedix
0.02
0.01
100.00%

Therma Bright Corporate Events

Stock SplitBusiness Operations and Strategy
Therma Bright Announces Share Consolidation to Streamline Share Structure
Neutral
Jul 3, 2025

Therma Bright Inc. announced a share consolidation effective July 8, 2025, where every eight pre-consolidation shares will be consolidated into one post-consolidation share. This move will reduce the number of shares from approximately 454 million to about 57 million, impacting the company’s stock options and warrants accordingly. The consolidation is expected to streamline the company’s share structure and potentially enhance its market positioning.

Delistings and Listing ChangesStock Split
Therma Bright Announces Share Consolidation to Enhance Financial Flexibility
Neutral
Jun 11, 2025

Therma Bright Inc. has announced a consolidation of its common shares, subject to TSX Venture Exchange approval, at a ratio of eight pre-Consolidation shares for one post-Consolidation share. This move is intended to provide the company with greater flexibility in structuring financings and business transactions, with no changes to its name or trading symbol expected.

Private Placements and FinancingBusiness Operations and Strategy
Therma Bright Proposes Warrant Amendments and Debt Settlements
Neutral
Jun 5, 2025

Therma Bright Inc. has announced its intention to amend the exercise price of 42,725,000 outstanding common share purchase warrants, pending approval from the TSX Venture Exchange. The amendment aims to adjust the exercise price to $0.05 per share until December 31, 2025, and $0.10 per share thereafter until expiration in 2027. Additionally, Therma Bright has negotiated debt settlements with creditors, proposing to settle $124,000 in debt by issuing 6,200,000 common shares at $0.02 per share, subject to TSXV acceptance. These strategic financial adjustments could impact the company’s market positioning and stakeholder interests.

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Therma Bright Advances InStatin Development with New Strategic Advisor and Preclinical Success
Positive
May 8, 2025

Therma Bright Inc. has announced significant progress in its InStatin project, which focuses on developing inhaled statin therapies for respiratory conditions. The company has appointed Professor Sir Peter Barnes, a renowned respiratory clinician, as a strategic advisor, and has completed a successful preclinical pharmacokinetic study. Additionally, Dr. Amir Zeki received a grant from the NIH for a statin efficacy study in monkeys. InStatin is also strengthening its intellectual property position with the help of an experienced IP attorney. These developments suggest a strategic entry into the asthma treatment market, potentially expediting regulatory approval compared to the COPD market.

Product-Related AnnouncementsExecutive/Board ChangesBusiness Operations and Strategy
Therma Bright Advances InStatin Development with Strategic Appointments and Preclinical Success
Positive
May 8, 2025

Therma Bright Inc. has announced significant progress in its InStatin project, which focuses on developing inhaled statin therapies for respiratory conditions. The company has appointed Professor Sir Peter Barnes as a strategic advisor, completed a rodent pharmacokinetic study, and received a grant for a statin efficacy study in monkeys. These developments, along with efforts to strengthen their intellectual property, position InStatin to advance towards clinical trials and potentially address unmet needs in respiratory disease treatment.

Product-Related AnnouncementsBusiness Operations and Strategy
Therma Bright Gains Market Traction with New Venowave Order
Positive
Apr 24, 2025

Therma Bright Inc. has secured an initial purchase order for 200 units of its Venowave VW5 product from a key distributor in the Durable Medical Equipment sector, indicating strong market confidence in its offerings. This development highlights the potential for significant follow-on orders and expansion opportunities, as the company continues to navigate the global trade environment and manage debt settlements through share issuance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025